BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026
Theranica has announced a major reimbursement milestone for Nerivio®, revealing that the FDA-cleared wearable Remote Electrical Neuromodulation (REN) therapy is now covered by health insurance plans representing 158 million insured Americans, surpassing half of the U.S. insured population. The achievement follows a series of nationwide payer coverage expansions and establishes Nerivio as the first and only FDA-cleared non-pharmacological migraine treatment to achieve commercial insurance coverage comparable to leading prescription migraine medicines. The milestone highlights growing confidence among healthcare payers in the device’s clinical effectiveness, safety profile, and health economic value, while significantly improving patient access to innovative, drug-free migraine treatment across the United States. The expanded reimbursement footprint also reflects increasing adoption of neuromodulation technology as an important component of modern migraine management.
Insurance Expansion Strengthens Access to FDA-Cleared Migraine Therapy
The latest reimbursement milestone follows the addition of coverage from a top-tier national health insurance provider along with numerous new regional coverage policies implemented across multiple U.S. states. As a result, commercial insurance coverage for Nerivio® has doubled over the past 15 months, representing one of the fastest reimbursement expansions achieved by a prescription therapeutic medical device. Today, more than 158 million covered lives have access to Nerivio when prescribed according to their individual health plan requirements, placing the therapy on par with many leading branded prescription migraine treatments.
This broad reimbursement network spans both national and regional health insurance providers, giving physicians greater flexibility to recommend evidence-based, non-drug migraine therapy without coverage limitations becoming a barrier to patient care. The achievement also represents an important shift toward broader recognition of FDA-cleared digital therapeutics and wearable neuromodulation devices within mainstream healthcare reimbursement systems.
Remote Electrical Neuromodulation Advances Modern Migraine Care
Advertisement
Nerivio® is the first and only FDA-cleared prescription Remote Electrical Neuromodulation (REN) therapy indicated for both the acute and preventive treatment of migraine in patients aged 8 years and older. Worn comfortably on the upper arm and controlled through a smartphone application, the wearable device activates the body’s natural Conditioned Pain Modulation (CPM) pathways using proprietary electrical stimulation, providing targeted migraine relief without medications, needles, systemic side effects, or drug interactions.
Supported by more than 35 peer-reviewed clinical studies, including randomized controlled trials and large real-world evidence analyses, Nerivio has demonstrated consistent clinical efficacy and a favorable long-term safety profile. As migraine affects approximately 39 million Americans, expanded insurance coverage significantly improves patient access to effective, non-pharmacological treatment options capable of reducing migraine frequency while providing on-demand symptom relief during attacks.
Theranica Continues Expanding Neuromodulation Innovation
The latest coverage achievement further strengthens Theranica’s position as a leader in neuromodulation therapeutics, supporting the company’s broader vision of expanding Remote Electrical Neuromodulation technology beyond migraine into additional chronic pain conditions. Company leadership emphasized that wider reimbursement enables physicians to make patient-centered treatment decisions based on clinical need rather than financial barriers while accelerating the adoption of evidence-based, non-drug therapies throughout neurological care. For patients whose insurance plans have not yet added coverage, Theranica continues to provide financial assistance through its Patient Assistance Program, helping reduce out-of-pocket expenses while reimbursement continues to expand.
As healthcare systems increasingly recognize the clinical and economic benefits of innovative neuromodulation technologies, Nerivio® is helping establish a new standard for migraine management by combining FDA-cleared wearable technology, strong clinical evidence, and broad commercial insurance access to improve outcomes for millions of patients living with chronic migraine.
Source: Theranica press release
